[1] TAKAHASHI K, YAMANAKA S．Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors [J]．Cell, 2006, 126(4): 663-676．
[2] TAKAHASHI K, TANABE K, OHNUKI M, et al．Induction of pluripotent stem cells from adult human fibroblasts by defined factors [J]．Cell, 2007, 131(5): 861-872．
[3] CAI J, LI W, SU H F, et al．Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells [J]．J Biol Chem,2010, 285(15): 11227-11234．
[4] WURIYANGHAI Y, MAKIYAMA T, SASAKI K, et al．Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation [J]．Heart Rhythm, 2018, 15(10): 1566-1574．
[5] VERDI J, TAN A, SHOAE-HASSANI A, et al．Endometrial stem cells in regenerative medicine [J]．J Biol Eng, 2014,8: 20．
[6] JOUNI M, SI-TAYEB K, ES-SALAH-LAMOUREUX Z, et al．Toward personalized medicine: Using cardiomyocytes differentiated from urine-derived pluripotent stem cells to recapitulate electrophysiological characteristics of type 2 long QT syndrome [J]．J Am Heart Assoc, 2015, 4(9):e002159．
[7] MALIK N, RAO M S．A review of the methods for human iPSC derivation [J]．Methods Mol Biol, 2013, 997: 23-33．
[8] RAAB S, KLINGENSTEIN M, LIEBAU S, et al．A comparative view on human somatic cell sources for iPSC generation [J]．Stem Cells Int, 2014, 2014: 768391．
[9] SOMMER C A, MOSTOSLAVSKY G．The evolving field of induced pluripotency: recent progress and future challenges [J]．J Cell Physiol, 2013, 228(2): 267-275．
[10] MOON S H, BAE D, JUNG T H, et al．From bench to market: Preparing human pluripotent stem cells derived cardiomyocytes for various applications [J]．Int J Stem Cells, 2017, 10(1): 1-11．
[11] MUMMERY C L, WARD D, PASSIER R．Differentiation of human embryonic stem cells to cardiomyocytes by coculture with endoderm in serum-free medium [J]．Curr Protoc Stem Cell Biol, 2007, 2(1): 1F．2．1-1F．2．14．
[12] SCHWARTZ P J．Practical issues in the management of the long QT syndrome: focus on diagnosis and therapy [J]．Swiss Med Wkly, 2013, 143: w13843．
[13] CHAI S, WAN X, RAMIREZ-NAVARRO A, et al．Physiological genomics identifies genetic modifiers of long QT syndrome type 2 severity [J]．J Clin Invest, 2018,128(3): 1043-1056．
[14] MALAN D, ZHANG M, STALLMEYER B, et al．Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction [J]．Basic Res Cardiol,2016, 111: 14．
[15] YAZAWA M, DOLMETSCH R E．Modeling Timothy syndrome with iPS cells [J]．J Cardiovasc Transl Res,2013, 6(1): 1-9．
[16] YAMAMOTO Y, MAKIYAMA T, HARITA T, et al．Allelespecific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation [J]．Hum Mol Genet, 2017, 26(9): 1670-1677．
[17] JUNG C B, MORETTI A, MEDEROS Y SCHNITZLER M, et al．Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia [J]．EMBO Mol Med,2012, 4(3): 180-191．
[18] MAIZELS L, HUBER I, ARBEL G, et al．Patient-specific drug screening using a human induced pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia type 2 [J]．Circ Arrhythm Electrophysiol, 2017,10(6): 004725．
[19] HOUSER S R, MARGULIES K B, MURPHY A M, et al．Animal models of heart failure: a scientific statement from the American Heart Association [J]．Circ Res, 2012;111(1): 131-150．
[20] LIANG P, SALLAM K, WU H, et al．Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome [J]．J Am Coll Cardiol, 2016, 68(19): 2086-2096．
[21] 李裕舒, 朱 峰．结构性心脏病的介入治疗进展[J]．临床心血管病杂志, 2017, 33(10): 928-930．
[22] ESCHENHAGEN T, CARRIER L．Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review [J]．Pflugers Arch,2019, 471(5): 755-768
[23] WANG L, KIM K, PARIKH S, et al．Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes [J]．J Mol Cell Cardiol, 2018, 114: 320-327．
[24] SCHICK R, MEKIES L N, SHEMER Y, et al．Functional abnormalities in induced Pluripotent Stem Cell-derived cardiomyocytes generated from titin-mutated patients with dilated cardiomyopathy [J]．PLoS One, 2018, 13(11):e0207548．
[25] LIN B, LI Y, HAN L, et al．Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy [J]．Dis Model Mech, 2015,8(5): 457-466．
[26] HUANG H P, CHEN P H, HWU W L, et al．Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification[J]．Hum Mol Genet, 2011, 20(24): 4851-4864．
[27] HICK A, WATTENHOFER-DONZé M, CHINTAWAR S,et al．Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia [J]．Dis Model Mech, 2013, 6(3): 608-621．
[28] WANG G, MCCAIN M L, YANG L, et al．Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies[J]．Nat Med, 2014, 20(6): 616-623．
[29] CALKINS H．Arrhythmogenic right ventricular dysplasia/cardiomyopathy-three decades of progress [J]．Circ J, 2015,79(5): 901-913．
[30] KRAMER J, OBEJERO-PAZ CA, MYATT G, et al．MICE models: superior to the HERG model in predicting Torsade de Pointes [J]．Sci Rep, 2013, 3: 2100．
[31] MULDER P, DE KORTE T, DRAGICEVIC E, et al．Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multielectrode array (MEA) technology: A conference report[J]．J Pharmacol Toxicol Methods, 2018, 91: 36-42．
[32] BLINOVA K, STOHLMAN J, VICENTE J, et al．Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias [J]．Toxicol Sci, 2017, 155(1):234-247．
[33] MATSA E, RAJAMOHAN D, DICK E, et al．Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation [J]．Eur Heart J, 2011, 32(8): 952-962．
[34] TERRENOIRE C, WANG K, TUNG K W, et al．Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics [J]．J Gen Physiol, 2013, 141(1): 61-72．
[35] PENTTINEN K, SWAN H, VANNINEN S, et al．Correction: antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using iPSC models [J]．PLoS One, 2015, 10(7): e0134746．
[36] SUN N, YAZAWA M, LIU J, et al．Patient-specific induced pluripotent stem cells as a model for familial dilated
cardiomyopathy [J]．Sci Transl Med, 2012, 4(130):130ra47．
[37] LIANG P, LAN F, LEE A S, et al．Drug screening using a library of human induced pluripotent stem cellderived
cardiomyocytes reveals disease-specific patterns of cardiotoxicity [J]．Circulation, 2013, 127(16): 1677-1691．
[38] BURRIDGE PW, LI YF, MATSA E, et al．Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity [J]．Nat Med, 2016, 22(5): 547-556．
[39] SHARMA A, BURRIDGE P W, MCKEITHAN W L, et al．High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells[J]．Sci Transl Med, 2017, 9(377): eaaf2584．